Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04699838 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Name: Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer — clinical trial record (NCT04699838)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 2

SponsorMuhammad Furqan

Started2021-04-20

View on ClinicalTrials.gov ↗

The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.

Amendment history 4 changes detected by DataLookout

2026-09-04

Primary completion pushed: 2026-07 → 2027-01

2026-09-04

Completion pushed: 2026-11 → 2027-04

2026-07-11

Trial status changed: Recruiting → Active, Not Recruiting

2026-06-09

Primary completion pushed: 2026-03 → 2026-07

Trial Details

NCT Number	NCT04699838
Lead Sponsor	Muhammad Furqan Collaborators: AstraZeneca
Conditions	Extensive Stage Small Cell Lung Cancer
Enrollment	30 participants
Start Date	2021-04-20
Primary Completion	2027-01 (estimated)
Study Completion	2027-04 (estimated)
Updated on ClinicalTrials.gov	2026-09-03